Schlieren-Based Arcoris Bio Raises €6.7 Million To Develop Biomarker Detection Platform

The round was co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB), as well as existing and new private investors.

“Attracting two lead investors with deep industry expertise is a strong validation of our technical and business strategy. This support empowers us in our mission of transforming biomarker detection and digital pathology,” commented Simon Restrepo, co-founder and CSO arcoris bio.

In 2025, European startups focused on life-science research tools, diagnostics, and biomarker detection technologies have continued to draw strong early-stage investment.

Read Also- Oslo’s WeWillWrite Raises €2M To Make Writing Fun Again As 73 Percent Of Students Struggle

Against this backdrop, Arcoris Bio’s €6.7 million Seed financing positions the Swiss company within a broader European push to industrialize and scale next-generation biomarker and diagnostic technologies.

Its MUSE platform, which focuses on multiplex biomarker detection and digital pathology, aligns with a wider trend toward high-sensitivity, data-rich diagnostic solutions.

While similar early-stage rounds in Sweden and France are smaller, Arcoris Bio’s Swiss base and strong venture backing place it among the more substantial players in the rapidly evolving European diagnostics tools landscape.

Matyas Vegh, CEO arcoris bio, added: “Securing this financing marks a major milestone for arcoris bio. In a challenging market, we are grateful for the trust our investors have placed in our vision. Their support empowers us to bring our innovations to market faster, strengthen our operations and scale to meet growing industry demand.”

Founded in 2022 by Simon Restrepo, Scott E. Fraser and entrepreneur H. Kaspar Binz, Arcoris Bio develops advanced technologies for biomarker detection in research and diagnostics. Its flagship MUSE platform offers universal, programmable signal amplification, enabling highly sensitive, multiplex assays and supporting the advancement of digital pathology.

Andreas Jenne, Investment Director at Ventura Ace, said: “We have been impressed by the arcoris bio team’s vision and early traction with industry partners. We believe MUSE represents a truly enabling technology for digital pathology.”

The funding will allow Arcoris Bio to industrialize its MUSE platform, expand strategic partnerships, and accelerate the launch of new products.

“arcoris bio’s MUSE technology fills a critical gap in the market to enable better diagnostics and applications like drug discovery or precision medicine. Its universal applicability is particularly exciting – MUSE acts like a molecular GPU, amplifying the capabilities of existing biomarker platforms and opening new paths for innovation,” highlighted Benedikt Klaes, Senior Investment Manager at ZEISS Ventures.

About Arcoris Bio

Arcoris Bio AG develops highly sensitive multiplex imaging kits and solutions for immunofluorescence, RNA FISH, and FACS. The company’s mission is to empower personalized medicine by providing advanced multiplex biomarker technologies, enabling researchers and clinicians to achieve more precise, data-rich insights for diagnostics, drug development and translational research.